Headlines about FibroGen (NASDAQ:FGEN) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. FibroGen earned a daily sentiment score of 0.20 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 43.8351862686183 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Shares of FibroGen (NASDAQ FGEN) traded up $0.55 on Friday, hitting $49.50. 337,707 shares of the stock traded hands, compared to its average volume of 523,167. The firm has a market capitalization of $4,023.57, a PE ratio of -24.26 and a beta of 1.55. FibroGen has a 1-year low of $21.05 and a 1-year high of $60.15. The company has a debt-to-equity ratio of 0.16, a current ratio of 10.83 and a quick ratio of 10.83.
A number of research analysts have commented on the stock. BidaskClub raised shares of FibroGen from a “sell” rating to a “hold” rating in a research report on Thursday, December 21st. ValuEngine cut shares of FibroGen from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Finally, Mizuho assumed coverage on shares of FibroGen in a research report on Wednesday, October 4th. They issued a “neutral” rating and a $61.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $65.67.
In other FibroGen news, Director Gerald Lema purchased 3,500 shares of FibroGen stock in a transaction dated Monday, December 4th. The shares were acquired at an average price of $46.70 per share, with a total value of $163,450.00. Following the completion of the transaction, the director now owns 3,500 shares of the company’s stock, valued at $163,450. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Jorma Routti sold 12,000 shares of the stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $47.25, for a total transaction of $567,000.00. Following the sale, the director now directly owns 133,840 shares in the company, valued at approximately $6,323,940. The disclosure for this sale can be found here. Insiders have sold 329,982 shares of company stock worth $16,234,608 in the last three months. Corporate insiders own 13.60% of the company’s stock.
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.